Trends in initial primary treatment approach and biomarker testing across social determinants of health in early-stage non-small cell lung cancer.

ABSTRACT:

Aim

To evaluate the impact of a comprehensive set of social determinants of health (SDOH) on treatments, timing, and key biomarker testing for early-stage non-small cell lung cancer (NSCLC).

Methods

Patients with the first diagnosis of stage I-III NSCLC from 1 January 2015 to 15 October 2023 and treated at community health systems in the United States were eligible for this retrospective database study. We summarized initial primary treatment and time-to-treatment initiation (TTI) by Social Vulnerability Index (SVI), primary care provider (PCP) shortage areas, household income, and insurance type. Data cutoff was 15 October 2024.

Results

Of 8501 patients with stage I-III NSCLC, 32% underwent surgery-only and 14% also received neoadjuvant and/or adjuvant therapy. Great

SUBMITTER: Hu X 

PROVIDER: S-EPMC12758337 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature